Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell directed gene therapy.

B C Engel1, D B Kohn

  • 1Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, CA 90027, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|May 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of adenosine deaminase deficiency.

Immunology today·2014
Same author

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Gene therapy·2010
Same author

Lentiviral vectors with amplified beta cell-specific gene expression.

Gene therapy·2009
Same author

Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors.

Gene therapy·2008
Same author

Gene therapy for childhood immunological diseases.

Bone marrow transplantation·2007
Same author

The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.

Gene therapy·2007
Same journal

The CD44 protein family: roles in embryogenesis and tumor progression.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Four varieties of voltage-gated proton channels.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Lurie's tubercle-count method to test TB vaccine efficacy in rabbits.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Optical spectroscopy of breast biopsies and human breast cancer xenografts in nude mice.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

The colostrum-deprived, artificially-reared, neonatal pig as a model animal for studying rotavirus gastroenteritis.

Frontiers in bioscience : a journal and virtual library·2017
Same journal

Action of polypeptide growth factors in colon cancer; development of new therapeutic approaches.

Frontiers in bioscience : a journal and virtual library·2017
See all related articles

Gene therapy aims to make cells resistant to HIV-1 by modifying hematopoietic stem cells. Current retroviral vector methods are ineffective, necessitating new lentiviral vector systems for efficient gene transfer and lasting resistance.

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Immunology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) infection and acquired immunodeficiency syndrome (AIDS) remain significant global health challenges.
  • Genetic modification of hematopoietic stem cells (HSCs) offers a promising strategy for durable HIV-1 resistance.
  • HSCs are ideal targets due to their capacity to generate diverse immune cells, including T lymphocytes and monocytes, crucial in HIV-1 pathogenesis.

Purpose of the Study:

  • To evaluate the potential of gene therapy for HIV-1 infection using hematopoietic stem cells.
  • To identify limitations of current gene transfer methods into HSCs.
  • To highlight the need for advanced vector systems for effective HIV-1 resistance.

Main Methods:

  • Review of existing literature on gene therapy approaches for HIV-1.

Related Experiment Videos

  • Analysis of retroviral vector-mediated gene transfer into human HSCs.
  • Discussion of clinical trial outcomes for gene-modified HSCs in HIV-1 patients.

    • Main Results:

    • Synthetic anti-HIV-1 genes have been developed to inhibit viral replication.
    • Current retroviral vectors (e.g., Moloney murine leukemia virus-derived) show minimal efficiency in gene transfer to human HSCs.
    • Clinical trials using retroviral vectors resulted in low or undetectable levels of gene-containing leukocytes post-infusion.

    Conclusions:

    • Existing gene transfer methods using retroviral vectors are insufficient for effective HIV-1 gene therapy.
    • Development of novel vector delivery systems, such as lentiviral vectors, is crucial.
    • Efficient gene transfer and persistent transgene expression are required for life-long HIV-1 resistance.